Paraproteinaemia after allo-SCT, association with alemtuzumab-based conditioning and CMV reactivation

P Medd, S Littlewood, R Danby, R Malladi, R Clifford, D Wareham, K Jeffery, B Ferry, D Roberts, A Peniket, T Littlewood

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)


Paraproteinaemia following allo-SCT is common. We analysed 91 consecutive patients undergoing allo-SCT; conditioning included alemtuzumab in 42% of the patients. Paraproteinaemia incidence at 2 years was 32%. In univariate analysis paraproteinaemia was associated with unrelated donor, age, recipient seropositivity for CMV and alemtuzumab conditioning (hazard ratio (HR) 3.93, P=0.0006). Paraproteinaemia was not associated with haematological diagnosis; disease status at transplant; varicella zoster, herpes simplex or EBV serology; reduced-intensity vs myeloablative conditioning or GVHD. CMV reactivation-more frequent in alemtuzumab recipients-was associated with paraproteinaemia (HR 7.52, P
Original languageEnglish
Pages (from-to)993-9
Number of pages7
JournalBone Marrow Transplantation
Issue number7
Publication statusPublished - Jul 2011


  • Antibodies, Neoplasm
  • Transplantation Conditioning
  • Humans
  • Retrospective Studies
  • Paraproteinemias
  • Virus Activation
  • Cytomegalovirus
  • Adult
  • Hematopoietic Stem Cell Transplantation
  • Middle Aged
  • Antibodies, Monoclonal, Humanized
  • Female
  • Male
  • Survival Analysis


Dive into the research topics of 'Paraproteinaemia after allo-SCT, association with alemtuzumab-based conditioning and CMV reactivation'. Together they form a unique fingerprint.

Cite this